Moreover, Qi et al. [12] found that treatment with RSL-3 (a GPX4 inhibitor) increased lipid peroxidation and the associated cell death, whereas treatment with iron chelators or liproxstatin-1 (a ferroptosis inhibitor) decreased the severity of NASH. This evidence concerns the gene GPX4 and metabolic dysfunction-associated steatohepatitis.